A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is highly aggressive neoplasm, with a median survival of
Source: Lung Cancer - Category: Cancer & Oncology Authors: Paolo Andrea Zucali, Matteo Perrino, Fabio De Vincenzo, Laura Giordano, Nadia Cordua, Federica D ’Antonio, Armando Santoro Source Type: research
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | Gleevec | Lung Cancer | Mesothelioma | Study